Abstract: The pathogenesis of chronic spontaneous urticaria (CSU) is complex, and second-generation H1 receptor antagonists are the first choice for its treatment. In recent years, the use of biologics such as omalizumab has significantly improved patient conditions. With the further study of the pathogenesis of CSU, new therapeutic targets continue to emerge, including Bruton tyrosine kinase inhibitors, anti-IGE monoclonal antibodies, spleen tyrosine kinase inhibitors, anti-sialic-binding immunoglobulin-like lectin 8 antibody, etc. In addition, adjuvant treatments such as autologous serum therapy, phototherapy and fecal flora transplantation have also shown some efficacy. These new drugs and therapeutic methods provide more options for the treatment of CSU. This paper reviews the progress in the treatment of CSU.

Key words: chronic spontaneous urticaria, pathogenesis, treatment, biologics